FULC — Fulcrum Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- $423.64m
- $187.42m
- $2.81m
- 53
- 11
- 79
- 45
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 8.82 | 19.2 | 6.34 | 2.81 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 84.2 | 80.4 | 100 | 119 | 113 |
Operating Profit | -84.2 | -71.6 | -81.1 | -113 | -111 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -82.7 | -70.8 | -80.8 | -110 | -97.3 |
Net Income After Taxes | -82.7 | -70.8 | -80.8 | -110 | -97.3 |
Net Income Before Extraordinary Items | |||||
Net Income | -82.7 | -70.8 | -80.8 | -110 | -97.3 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -89.8 | -70.8 | -80.8 | -110 | -97.3 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -3.96 | -2.79 | -2.29 | -2.43 | -1.59 |